Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Starting treatment news

Show

From To
Back to the future with CD4 testing: Improving HIV care in low- and middle-income countries

A practical resource-based public health approach for the rapid initiation of antiretroviral therapy in HIV-infected individuals living in low- and middle-income countries could save thousands of lives, according to an Essay published January 15 in the open-access journal PLOS Medicine by Mark Tenforde of the University of Washington School of Medicine, and colleagues.

Published
16 January 2019
From
Science Daily
‘RAPID’ HIV treatment initiation a success in San Francisco

Populations considered hard to treat or engage in care can benefit from same-day antiretroviral treatment as part of a clinic offering social safety-net interventions.

Published
08 January 2019
From
AVERT
HIV clinic's hardest battle in treating people is helping them to overcome the social stigma

Jason, who is using a pseudonym, is a heterosexual black man of African heritage. He is typical of the patients seen at the clinic in University Hospital Lewisham. There are 850 patients on the books, more than 50 per cent are heterosexual and most of African origin. Many live on the poverty line and struggle with mental health problems. But the biggest challenge facing the team is the issue of stigma.

Published
10 December 2018
From
Evening Standard
Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA in Treatment-Naïve Adults with HIV-1

New Phase 3 AMBER study data continues to demonstrate high rates of virologic suppression at 96 weeks in ART-naïve adults with HIV-1 when treated with SYMTUZA

Published
01 November 2018
From
Janssen press release
Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Biktarvy Showed High Efficacy and High Barrier to Resistance Through 96 Weeks

Published
01 November 2018
From
Gilead press release
Rapid Initiation of HIV Care: Assessing Safety and Efficacy

Discussion with Gregory Huhn, MD

Published
16 October 2018
From
Infectious Disease Advisor
PET Scans May Predict Who Gets Inflammatory Reaction to HIV Treatment Start

The imaging method known as a PET scan may be able to predict who among those starting antiretroviral (ARV) treatment with an immune system highly damaged by HIV will develop HIV-associated immune reconstitution syndrome (IRIS).

Published
26 September 2018
From
Poz
What you need to know about HIV two-drug regimens

Integrase inhibitors—potent antiretrovirals that quickly and powerfully suppress HIV—have allowed HIV researchers and clinicians to explore dosing regimens that involve fewer than three or four drugs. Proponents of dual therapy say that effective regimens involving fewer drugs will lower costs, decrease pill burden and reduce the potential for drug-drug interactions and side effects. But is it that simple?

Published
28 August 2018
From
BETA blog
Starting HIV treatment at diagnosis slashes drop out, drug failure rates, China study finds

Patients diagnosed with HIV who started antiretroviral treatment within 30 days had significantly lower rates of dropping out of treatment, and higher rates successful treatment, than those who started later, particularly those who started more than three months after their diagnosis, a study in China has found.

Published
04 June 2018
From
Science Speaks
South Africa: Birth defects fears prompt warnings about new ARV

Despite the public concern globally, very little has been said about the impact of the safety warning about dolutegravir on South Africa, the country with the largest HIV treatment programme in the world. The National Department of Health had already planned to introduce a dolutegravir-based first line regimen to replace the existing regimen, hoping to switch the majority of patients starting from last month.

Published
29 May 2018
From
Health-e
← First12345...18Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.